Responders did not differ from non-responders with regard to age, sex, migraine diagnosis [EM, CM], age at migraine onset, migraine disease duration, comorbidities [depression, anxiety, and hypertension], the type of ligand mAb before initiation of erenumab, MHD before initiation of CGRP ligand/receptor mAb treatment, the duration of the break between treatments, and the treatment dose of erenumab [70 mg, 140 mg] (Supplementary Table 2). This evidence concerns the gene CALCA and migraine disorder.